This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Alimera Sciences Past Earnings Performance

Past criteria checks 0/6

Alimera Sciences's earnings have been declining at an average annual rate of -37.8%, while the Pharmaceuticals industry saw earnings declining at 0.3% annually. Revenues have been growing at an average rate of 10.3% per year.

Key information

-37.8%

Earnings growth rate

-16.0%

EPS growth rate

Pharmaceuticals Industry Growth	6.0%
Revenue growth rate	10.3%
Return on equity	-37.9%
Net Margin	-15.3%
Last Earnings Update	30 Jun 2024

Recent past performance updates

Recent updates

Alimera confirmatory trial testing Iluvien in diabetic macular edema patients shows positive data

Oct 06

Alimera's eye inflammation Iluvien injection granted reimbursement in Ireland

Sep 20

Alimera granted reimbursement in Portugal for eye inflammation Iluvien injection

Aug 09

Alimera granted pricing, reimbursement in France for eye inflammation Iluvien injection

Jul 22

Alimera gets Italian nod for its Iluvien injection to treat a form of eye inflammation

Jul 08

Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?

Mar 24

Is Alimera Sciences, Inc. (NASDAQ:ALIM) Worth US$5.7 Based On Its Intrinsic Value?

Nov 06

Why Alimera Sciences' (NASDAQ:ALIM) Earnings Are Weaker Than They Seem

Aug 24

Alimera Sciences' (NASDAQ:ALIM) Shareholders Are Down 75% On Their Shares

Feb 11

Alimera Sciences (ALIM) Investor Presentation - Slideshow

Nov 18

Revenue & Expenses Breakdown

How Alimera Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGM:ALIM Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Jun 24	100	-15	54	17
31 Mar 24	90	-23	51	17
31 Dec 23	81	-21	46	17
30 Sep 23	68	-21	41	16
30 Jun 23	59	-25	40	17
31 Mar 23	56	-17	39	17
31 Dec 22	54	-18	39	16
30 Sep 22	54	-18	40	16
30 Jun 22	53	-17	39	15
31 Mar 22	60	-7	38	14
31 Dec 21	59	-4	36	14
30 Sep 21	59	-1	34	13
30 Jun 21	59	2	33	12
31 Mar 21	47	-8	31	10
31 Dec 20	51	-5	32	10
30 Sep 20	54	-4	34	10
30 Jun 20	55	-6	36	10
31 Mar 20	56	-9	39	11
31 Dec 19	54	-10	39	11
30 Sep 19	52	-12	38	11
30 Jun 19	50	19	37	11
31 Mar 19	50	22	37	11
31 Dec 18	47	17	37	11
30 Sep 18	41	11	38	11
30 Jun 18	39	-22	38	11
31 Mar 18	39	-23	37	11
31 Dec 17	36	-22	36	10
30 Sep 17	37	-21	38	10
30 Jun 17	36	-25	39	10
31 Mar 17	35	-29	43	11
31 Dec 16	34	-33	45	12
30 Sep 16	29	-38	44	13
30 Jun 16	28	-30	43	14
31 Mar 16	24	-32	42	15
31 Dec 15	22	-31	42	15
30 Sep 15	18	-30	41	14
30 Jun 15	14	-35	37	14
31 Mar 15	10	-26	32	12
31 Dec 14	8	-37	27	12
30 Sep 14	8	-41	24	11
30 Jun 14	6	-36	25	9
31 Mar 14	4	-58	26	9
31 Dec 13	2	-51	24	9
30 Sep 13	1	-42	26	8

Quality Earnings: ALIM is currently unprofitable.

Growing Profit Margin: ALIM is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ALIM is unprofitable, and losses have increased over the past 5 years at a rate of 37.8% per year.

Accelerating Growth: Unable to compare ALIM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALIM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13%).

Return on Equity

High ROE: ALIM has a negative Return on Equity (-37.89%), as it is currently unprofitable.

This company has been acquired

Alimera Sciences Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Alimera Sciences, Inc. to Report Q1, 2024 Results on May 14, 2024

Alimera Sciences, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Third quarter 2023 earnings released: US$0.06 loss per share (vs US$0.75 loss in 3Q 2022)

Alimera Sciences, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Recent updates

ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) completed the acquisition of Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others.

ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) completed the acquisition of Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others.

Alimera Sciences: Deal Closing After All, CVR Still Attractive

Alimera Sciences: Cheap CVR Optionality

ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) signed a definitive agreement to acquire Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others for approximately $300 million.

Market Still Lacking Some Conviction On Alimera Sciences, Inc. (NASDAQ:ALIM)

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Alimera Sciences, Inc. to Report Q1, 2024 Results on May 14, 2024

Forecast breakeven date pushed back to 2025

Price target increased by 14% to US$8.00

Alimera Sciences, Inc. Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network

Alimera Sciences, Inc. Provides Revenue Guidance for the Year 2024

Alimera Sciences, Inc. Provides Revenue Guidance for the Year 2024

Alimera Sciences, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Alimera Sciences, Inc.'s (NASDAQ:ALIM) Shares Not Telling The Full Story

Alimera Sciences, Inc. Names Elliot Maltz as Chief Financial Officer

Is Alimera Sciences (NASDAQ:ALIM) A Risky Investment?

Alimera Sciences, Inc. Appoints Todd Wood as President of U.S. Operations

Alimera Sciences, Inc Appoints Maggie A. Pax to its Board of Directors

Alimera Announces Scientific Data Highlighting ILUVIEN to Be Presented at the American Academy of Ophthalmology

Third quarter 2023 earnings released: US$0.06 loss per share (vs US$0.75 loss in 3Q 2022)

Alimera Sciences, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Investors Holding Back On Alimera Sciences, Inc. (NASDAQ:ALIM)

Alimera Sciences, Inc. Announces Management Appointments

Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?

New major risk - Shareholder dilution

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Alimera Sciences, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Alimera Sciences, Inc., Annual General Meeting, Aug 01, 2023

Forecast breakeven date moved forward to 2024

Alimera Sciences, Inc. entered into an agreement to acquire YUTIQ® from EyePoint Pharmaceuticals, Inc. for $82.5 million.

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Alimera Sciences, Inc. to Report Q1, 2023 Results on May 15, 2023

Less than half of directors are independent

Forecast breakeven date pushed back to 2025

Full year 2022 earnings: EPS and revenues miss analyst expectations

Alimera Sciences, Inc. Appoints Russell L. Skibsted as Senior Vice President

Alimera Sciences, Inc. Announces Abstracts Regarding Consensus Among US Retina Specialists and Reduced Retinal Thickness Variability Leading to Improved Visual Outcomes Following ILUVIEN®Administration

Price target decreased to US$10.50

Insufficient new directors

Alimera Sciences, Inc. Announces Resignation of J. Philip Jones as CFO, Effective from November 28, 2022

Alimera Sciences, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Alimera Sciences, Inc. Announces Paladin Phase 4 Study Confirms ILUVIEN Patients' Reduced Need for Multiple Treatments

Alimera confirmatory trial testing Iluvien in diabetic macular edema patients shows positive data

Alimera's eye inflammation Iluvien injection granted reimbursement in Ireland

Alimera Sciences, Inc. Announces Multiple Abstracts Highlighting ILUVIEN® Real World Data at EURETINA Annual Congress

Alimera granted reimbursement in Portugal for eye inflammation Iluvien injection

Insufficient new directors

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Alimera Sciences, Inc. to Report Q2, 2022 Results on Jul 27, 2022

Alimera granted pricing, reimbursement in France for eye inflammation Iluvien injection

Alimera gets Italian nod for its Iluvien injection to treat a form of eye inflammation

Alimera Sciences, Inc., Annual General Meeting, Jul 12, 2022

Alimera Sciences, Inc. Announces that Phase 4 PALADIN Study Confirms Positive Predictive Value of Corticosteroid Course Prior to ILUVIEN Use for IOP Outcomes

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Forecast to breakeven in 2024

Alimera Sciences, Inc. to Report Q1, 2022 Results on May 09, 2022

Price target decreased to US$13.00

Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?

Consensus EPS estimates fall by 93%

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Alimera Sciences, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Is Alimera Sciences, Inc. (NASDAQ:ALIM) Worth US$5.7 Based On Its Intrinsic Value?

President recently bought US$125k worth of stock

Third quarter 2021 earnings released: US$0.60 loss per share (vs US$0.12 loss in 3Q 2020)

Investor sentiment deteriorated over the past week

Alimera Sciences Announces National Pricing and Reimbursement Granted for ILUVIEN for DME in Belgium